Candel Therapeutics, Inc. financial data

Symbol
CADL on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
117 Kendrick Street, Suite 450, Needham, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 253 % -76.3%
Debt-to-equity 369 % +430%
Return On Equity -629 % -732%
Return On Assets -134 % -201%
Operating Margin -27.8K % -35%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 32.1M shares +10.9%
Common Stock, Shares, Outstanding 31.1M shares +7.42%
Entity Public Float 28.2M USD -61%
Common Stock, Value, Issued 303K USD +4.48%
Weighted Average Number of Shares Outstanding, Basic 29.9M shares +3.31%
Weighted Average Number of Shares Outstanding, Diluted 29.9M shares +3.31%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 125K USD 0%
Research and Development Expense 22.2M USD +1.99%
General and Administrative Expense 13.5M USD -7.16%
Operating Income (Loss) -35.7M USD +1.5%
Nonoperating Income (Expense) -14.3M USD -457%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -50M USD -55.3%
Earnings Per Share, Basic -1.7 USD/shares -53.2%
Earnings Per Share, Diluted -1.7 USD/shares -53.2%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 21.5M USD -58.7%
Assets, Current 22.7M USD -57.4%
Property, Plant and Equipment, Net 2.72M USD -31.7%
Operating Lease, Right-of-Use Asset 684K USD -27.2%
Assets 26.5M USD -54.9%
Accounts Payable, Current 433K USD -9.79%
Employee-related Liabilities, Current 2.02M USD +3.54%
Accrued Liabilities, Current 3.22M USD -8.01%
Liabilities, Current 14M USD +71.5%
Operating Lease, Liability, Noncurrent 698K USD -43.6%
Liabilities 36.5M USD +30.5%
Retained Earnings (Accumulated Deficit) -167M USD -42.5%
Stockholders' Equity Attributable to Parent -9.97M USD -132%
Liabilities and Equity 26.5M USD -54.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -8.44M USD +22%
Net Cash Provided by (Used in) Financing Activities -1.26M USD
Net Cash Provided by (Used in) Investing Activities -7K USD -137%
Common Stock, Shares Authorized 150M shares 0%
Common Stock, Shares, Issued 31.2M shares +7.38%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -9.7M USD +10.2%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 21.7M USD -58.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 549K USD +9.8%
Deferred Tax Assets, Valuation Allowance 40.5M USD +39%
Deferred Tax Assets, Gross 41M USD +36.9%
Operating Lease, Liability 1.24M USD -28.3%
Depreciation 981K USD 0%
Payments to Acquire Property, Plant, and Equipment 7K USD -94.9%
Lessee, Operating Lease, Liability, to be Paid 1.33M USD -30.8%
Property, Plant and Equipment, Gross 5.31M USD -4.81%
Operating Lease, Liability, Current 539K USD +10.5%
Lessee, Operating Lease, Liability, to be Paid, Year Two 415K USD -32.3%
Lessee, Operating Lease, Liability, to be Paid, Year One 613K USD +2.51%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 92K USD -52.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three 415K USD 0%
Deferred Tax Assets, Operating Loss Carryforwards 23.1M USD +30.4%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 415K USD -32.3%
Operating Lease, Payments 587K USD +11%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 230K USD +39.4%
Deferred Tax Assets, Net of Valuation Allowance 501K USD -39.5%
Share-based Payment Arrangement, Expense 4.51M USD +58.6%
Interest Expense 2.56M USD -12%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%